Barclays lowered the firm’s price target on 10x Genomics (TXG) to $15 from $18 and keeps an Overweight rating on the shares.Maximize Your ...
Hosted on MSN2d
10x Genomics (NASDAQ:TXG) Exceeds Q4 Expectations But Full-Year Sales Guidance Misses ExpectationsBiotech company 10x Genomics (NASDAQ:TXG) reported Q4 CY2024 results , but sales fell by 10.3% year on year to $165 million.
Despite a challenging macro environment, 10x Genomics Inc (TXG) focuses on product innovation and biopharma expansion to ...
Genomics company 10x and Harvard University have agreed to resolve a patent lawsuit against 10x's rival Vizgen four days into ...
PLEASANTON, Calif. (AP) — PLEASANTON, Calif. (AP) — 10x Genomics Inc. (TXG) on Wednesday reported a loss of $49 million in its fourth quarter. The Pleasanton, California-based company said it had a ...
On Wednesday, 10x Genomics Inc (NASDAQ:TXG) reported a fourth-quarter EPS loss of $(0.40), missing the consensus estimate of ...
The website you are visiting is protected and accelerated by Incapsula. Your computer may have been infected by malware and ...
CEO Serge Saxonov highlighted strong growth across platforms, with total revenue for Q4 2023 reaching $184 million, an 18% increase year-over-year. Spatial products contributed significantly, with ...
Zacks.com on MSN3d
Seeking Clues to 10x Genomics (TXG) Q4 Earnings? A Peek Into Wall Street Projections for Key MetricsBesides Wall Street's top -and-bottom-line estimates for 10x Genomics (TXG), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback